Christopher Raymond

Piper Sandler | Healthcare

Christopher Raymond is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #288 out of 4508 analysts, they have issued 18 stock ratings with a success rate of 91.61% and an average return of 61.55%.

With 18 ratings to date, Christopher Raymond is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 91.61% and an average return of 61.55%, highlighting promising potential as their track record develops further.

#288

Out of 4508

18

Total Ratings

+91.61%

Success Rate

+61.55%

Average Return

Recent Ratings Analysis

ARDX

Jan 09, 2026

Target

$16.00

Current

$7.74

Performance

0.00%

Christopher Raymond rated ARDX as Overweight on Jan 09, 2026, setting a price target of 16. Shares have remained stable near 7.74, leaving the 16 target still in play.

LXEO

Dec 18, 2025

Target

$25.00

Current

$10.54

Performance

%

On Dec 18, 2025, LXEO was given a Strong Buy rating by Christopher Raymond, with a target price of 25. The stock traded sideways with a % move, keeping the bullish thesis unresolved.

TSHA

Oct 21, 2025

Target

$13.00

Current

$4.98

Performance

-3.30%

TSHA received a Strong Buy rating from Christopher Raymond on Oct 21, 2025, aiming for 13. Price action was muted, as shares hovered around 4.98 despite the bullish outlook.

MGTX

Oct 21, 2025

Target

$29.00

Current

$7.41

Performance

-19.98%

On Oct 21, 2025, Christopher Raymond published a Strong Buy outlook on MGTX, with a target of 29. Market action contradicted the Buy thesis, as shares slipped to 7.41.

ABBV

Oct 10, 2025

Target

$284.00

Current

$220.08

Performance

-4.52%

Christopher Raymond on Oct 10, 2025 assigned ABBV a Overweight rating, with a price target of 284. The recommendation remains pending validation as shares consolidate around 220.08.

ABVX

Jul 23, 2025

Target

$70.00

Current

$114.40

Performance

66.76%

On Jul 23, 2025, Christopher Raymond reaffirmed ABVX with a Overweight rating, targeting 70. The recommendation was supported by strong follow-through as the stock rose from 114.4 to 114.4.

ALXO

Mar 06, 2025

Target

$9.00

Current

$1.35

Performance

3.05%

ALXO was rated Overweight by Christopher Raymond on Mar 06, 2025, with a price objective of 9. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

BMRN

Feb 20, 2025

Target

$126.00

Current

$58.95

Performance

-14.23%

On Feb 20, 2025, Christopher Raymond initiated coverage on BMRN with a Overweight rating and target of 126. The Buy call has yet to be validated as shares remain 67.05 away from the target.

BIIB

Feb 18, 2025

Target

$135.00

Current

$187.62

Performance

37.38%

Christopher Raymond issued a Neutral recommendation for BIIB on Feb 18, 2025, price target set at 135. A neutral call gave way to stronger-than-expected performance, closing in on 135.

QTTB

Feb 11, 2025

Target

$4.00

Current

$3.60

Performance

25.00%

On Feb 11, 2025, QTTB was evaluated by Christopher Raymond, who gave a Neutral rating and target of 4. Investors who stayed in despite the Hold saw upside of 25.00%.

VRTX

Jan 27, 2025

Target

$533.00

Current

$463.86

Performance

4.50%

Christopher Raymond rated VRTX as Overweight on Jan 27, 2025, setting a price target of 533. Shares have remained stable near 463.86, leaving the 533 target still in play.

REGN

Jan 27, 2025

Target

$1013.00

Current

$796.55

Performance

16.33%

On Jan 27, 2025, REGN was given a Overweight rating by Christopher Raymond, with a target price of 1013. The stock rallied 16.33% after the rating, narrowing the gap to the target of 1013 and validating the bullish stance.

BPMC

Jan 27, 2025

Target

$119.00

Current

$129.46

Performance

13.68%

BPMC received a Neutral rating from Christopher Raymond on Jan 27, 2025, aiming for 119. Investors saw gains of 13.68% that the cautious stance didn’t fully capture.

INZY

Jan 13, 2025

Target

$30.00

Current

$4.00

Performance

132.56%

On Jan 13, 2025, Christopher Raymond published a Overweight outlook on INZY, with a target of 30. Shares gained 132.56%, underscoring the accuracy of the bullish outlook toward 30.

RARE

Jan 13, 2025

Target

$140.00

Current

$22.51

Performance

-47.85%

Christopher Raymond on Jan 13, 2025 assigned RARE a Overweight rating, with a price target of 140. The call has struggled to gain traction, with shares losing 47.85%.

MNPR

Jan 10, 2025

Target

$72.00

Current

$63.00

Performance

148.52%

On Jan 10, 2025, Christopher Raymond reaffirmed MNPR with a Overweight rating, targeting 72. The recommendation was supported by strong follow-through as the stock rose from 63 to 63.

ACRS

Nov 18, 2024

Target

$13.00

Current

$2.64

Performance

-15.92%

ACRS was rated Overweight by Christopher Raymond on Nov 18, 2024, with a price objective of 13. This case shows how bullish projections can fail, with the stock now below 2.64.

BHVN

Sep 23, 2024

Target

$76.00

Current

$11.11

Performance

-75.82%

On Sep 23, 2024, Christopher Raymond initiated coverage on BHVN with a Overweight rating and target of 76. The Buy call has yet to be validated as shares remain 64.89 away from the target.

IOBT

Sep 03, 2024

Target

$10.00

Current

$0.56

Performance

-43.76%

Christopher Raymond issued a Overweight recommendation for IOBT on Sep 03, 2024, price target set at 10. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

TYRA

Aug 15, 2024

Target

$33.00

Current

$29.31

Performance

33.23%

On Aug 15, 2024, TYRA was evaluated by Christopher Raymond, who gave a Overweight rating and target of 33. This case illustrates how a timely bullish rating can translate into tangible gains of 33.23%.

SLDB

Mar 14, 2024

Target

$20.00

Current

$5.29

Performance

-56.92%

Christopher Raymond rated SLDB as Overweight on Mar 14, 2024, setting a price target of 20. The stock has underperformed, dropping 56.92% despite the bullish target of 20.

Frequency Asked Questions

Who is Christopher Raymond?

Christopher Raymond is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Christopher Raymond's success rate?

Christopher Raymond currently has a success rate of +91.61%.

How many ratings has Christopher Raymond issued?

Christopher Raymond has issued 18 stock ratings so far.

What is the average return of Christopher Raymond's calls?

Their stock ratings have generated an average return of +61.55%.

What is Christopher Raymond's ranking?

Christopher Raymond is ranked #288 out of 4508 analysts.

What types of ratings does Christopher Raymond give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Christopher Raymond?

You can follow Christopher Raymond by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Christopher Raymond?

Their latest rating was a Buy on ARDX issued on 2026-01-09.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep